The market style is shifting towards trend-following, with a focus on high-positioned hotspots such as computing hardware and innovative pharmaceuticals, presenting opportunities for expansion and extension.

Track the entire lifecycle of the main Sector.

cls.cn21:27 ET

Fujian Cosunter Pharmaceutical (300436.SZ): The stock price has risen significantly in the short term, but there have been no major changes in the fundamentals.

Fujian Cosunter Pharmaceutical (300436.SZ) announced a serious abnormal fluctuation in stock price, stating that as of July 15, 2025, ...

Zhitong FinanceJul 16 08:03 ET

Cosunter Pharmaceutical Wins Breakthrough Therapy Status for CHB Drug in China

MT NewswiresJul 11 02:34 ET

Fujian Cosunter Pharmaceutical (SZSE:300436) Soars 28% This Week, Taking One-year Gains to 171%

Simply Wall StJul 3 21:08 ET

The directory of innovative drugs for commercial insurance has been officially included! The national negotiation plan for 2025 has begun to seek opinions, and the "dual export" of innovative drugs is being launched simultaneously.

① The directory of commercial innovative drugs is expected to be officially introduced for national discussion. ② Eligible exclusive drugs can be declared separately for the commercial insurance innovative drug directory or simultaneously for both the commercial insurance innovative drug directory and the basic directory. ③ Some enterprises have informed the Financial Association reporter that they will actively participate in the declaration of the commercial insurance innovative drug directory.

cls.cnJul 1 08:10 ET

Study Times: Efforts should be made to accelerate the research and development of innovative drugs and improve the multi-level Capital Markets support for pharmaceutical companies.

The article published in the 'Study Times' states that developing innovative drugs is a fundamental way to address major diseases and ensure pharmaceutical safety, as well as a new driving force for promoting high-quality economic development. China's innovative drugs need to strengthen basic research, deepen review and approval reforms, improve the support of a multi-level Capital Markets for pharmaceutical companies, optimize the investment and financing system, enhance talent training and introduction, deepen international cooperation, and promote the high-quality development of innovative drugs.

wallstreetcnJun 24 20:42 ET